Financials
| Interim Half Year Results 2025 | Sep. 30, 2025 |
| Posting of Annual Report and Revised Notice of AGM | Jun. 09, 2025 |
| Interim Results | Sep. 30, 2024 |
| Full Year Results | Apr. 30, 2024 |
| Interim Results for the Period Ending 30 June 2023 | Sep. 28, 2023 |
| Preliminary Results | Apr. 25, 2023 |
| Interim Results for the Period Ended 30 June 2022 | Sep. 29, 2022 |
Proxies
| Result of AGM | Jul. 02, 2025 |
| Result of AGM | Jun. 26, 2024 |
| Posting of Annual Report and Notice of AGM | May. 31, 2024 |
| Result of General Meeting | Mar. 18, 2024 |
| Result of Annual General Meeting | Jun. 28, 2023 |
| Posting of Annual Report and Notice of AGM | Jun. 02, 2023 |
| Result of Annual General Meeting | Jun. 23, 2022 |
Ownership Update
| Director/PDMR Shareholdings and TVR | Sep. 02, 2024 |
| Director/PDMR Shareholding | Sep. 29, 2023 |
| Director/PDMR Shareholding | Nov. 08, 2022 |
| Director/PDMR Shareholding | Oct. 20, 2022 |
| Holding(s) in Company | Jun. 09, 2021 |
| Director/PDMR Shareholding | Oct. 22, 2020 |
| Holding(s) in Company | Aug. 11, 2020 |
Announcements
| Block Listing Six Monthly Return | Oct. 27, 2025 |
| Avacta presents preclinical data at AACR-NCI-EORTC | Oct. 27, 2025 |
| Notice of Investor Presentation | Oct. 23, 2025 |
| Equity fundraise of £16 million | Oct. 20, 2025 |
| Avacta Presents Phase 1a Data for Faridoxorubicin | Oct. 20, 2025 |
| Avacta to present data at EORTC-NCI-AACR | Oct. 13, 2025 |
| Notice of Interim Results | Sep. 15, 2025 |